MBD2 serves as a viable target against pulmonary fibrosis by inhibiting macrophage M2 program
Yi Wang(Chinese Academy of Sciences), Cong‐Yi Wang(Ministry of Education of the People's Republic of China), Huihui Yue(Tongji Hospital), Ting Yuan(Goethe University Frankfurt), Jianping Zhao(Xinjiang University), Lizong Rao(Central South University), Guorao Wu(Tongji Hospital), Longmin Chen(Tongji Hospital), Qing Zhou(Tongji Hospital), Fei Sun(Ningxia Medical University), Fei Xiong(Capital Medical University), Lei Zhang(Macau University of Science and Technology), Shu Zhang(Tongji Hospital), Jia Song(Ministry of Education of the People's Republic of China), Biwen Mo(Guilin Medical University), Yongjian Xu(Ningbo University), Qilin Yu(Tongji Hospital), Ping Yang(Southwest Medical University), Faxi Wang(Wuhan University), Weining Xiong(Shanghai Ninth People's Hospital), Huilan Zhang(Tongji Hospital)
Cited by 233
Related Papers
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
|The Lancet|2020|51.8k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan
|Journal of Allergy and Clinical Immunology|2020|2.4k
Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study
|The Lancet|2018|1.8k
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
|Signal Transduction and Targeted Therapy|2021|1.7k